NTLA PE Ratio & Valuation,Is NTLA Overvalued

NTLA Relative Valuation

NTLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NTLA is overvalued; if below, it's undervalued.

Historical Valuation

Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 24.54 is considered Fairly compared with the five-year average of -11.12. The fair price of Intellia Therapeutics Inc (NTLA) is between 5.25 to 50.18 according to relative valuation methord.

Relative Value

Fair Zone

5.25-50.18

Current Price：8.97

Fair

-2.27

-0.99

EV/EBITDA

Intellia Therapeutics Inc. (NTLA) has a current EV/EBITDA of -0.99. The 5-year average EV/EBITDA is -8.43. The thresholds are as follows: Strongly Undervalued below -26.46, Undervalued between -26.46 and -17.44, Fairly Valued between 0.59 and -17.44, Overvalued between 0.59 and 9.60, and Strongly Overvalued above 9.60. The current Forward EV/EBITDA of -0.99 falls within the Historic Trend Line -Fairly Valued range.

-1.01

EV/EBIT

Intellia Therapeutics Inc. (NTLA) has a current EV/EBIT of -1.01. The 5-year average EV/EBIT is -9.01. The thresholds are as follows: Strongly Undervalued below -30.71, Undervalued between -30.71 and -19.86, Fairly Valued between 1.83 and -19.86, Overvalued between 1.83 and 12.68, and Strongly Overvalued above 12.68. The current Forward EV/EBIT of -1.01 falls within the Historic Trend Line -Fairly Valued range.

24.54

Intellia Therapeutics Inc. (NTLA) has a current PS of 24.54. The 5-year average PS is 90.84. The thresholds are as follows: Strongly Undervalued below -62.80, Undervalued between -62.80 and 14.02, Fairly Valued between 167.66 and 14.02, Overvalued between 167.66 and 244.48, and Strongly Overvalued above 244.48. The current Forward PS of 24.54 falls within the Historic Trend Line -Fairly Valued range.

-2.93

P/OCF

Intellia Therapeutics Inc. (NTLA) has a current P/OCF of -2.93. The 5-year average P/OCF is -12.01. The thresholds are as follows: Strongly Undervalued below -33.31, Undervalued between -33.31 and -22.66, Fairly Valued between -1.37 and -22.66, Overvalued between -1.37 and 9.28, and Strongly Overvalued above 9.28. The current Forward P/OCF of -2.93 falls within the Historic Trend Line -Fairly Valued range.

-2.85

P/FCF

Intellia Therapeutics Inc. (NTLA) has a current P/FCF of -2.85. The 5-year average P/FCF is -13.07. The thresholds are as follows: Strongly Undervalued below -39.25, Undervalued between -39.25 and -26.16, Fairly Valued between 0.02 and -26.16, Overvalued between 0.02 and 13.11, and Strongly Overvalued above 13.11. The current Forward P/FCF of -2.85 falls within the Historic Trend Line -Fairly Valued range.

Intellia Therapeutics Inc (NTLA) has a current Price-to-Book (P/B) ratio of 1.40. Compared to its 3-year average P/B ratio of 2.21 , the current P/B ratio is approximately -36.79% higher. Relative to its 5-year average P/B ratio of 4.78, the current P/B ratio is about -70.82% higher. Intellia Therapeutics Inc (NTLA) has a Forward Free Cash Flow (FCF) yield of approximately -39.49%. Compared to its 3-year average FCF yield of -21.60%, the current FCF yield is approximately 82.88% lower. Relative to its 5-year average FCF yield of -14.41% , the current FCF yield is about 173.99% lower.

1.40

P/B

Median3y

2.21

Median5y

4.78

-39.49

FCF Yield

Median3y

-21.60

Median5y

-14.41

Competitors Valuation Multiple

The average P/S ratio for NTLA's competitors is 13.74, providing a benchmark for relative valuation. Intellia Therapeutics Inc Corp (NTLA) exhibits a P/S ratio of 24.54, which is 78.55% above the industry average. Given its robust revenue growth of 51.27%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NTLA decreased by 22.64% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 9.11M to 13.78M.

The secondary factor is the P/E Change, contributed -23.27%to the performance.

Overall, the performance of NTLA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

51.27%

9.11M → 13.78M

Revenue Growth

-50.64%

-1.49K → -735.19

Margin Expansion

-23.27%

-2.77 → -2.12

P/E Change

-22.64%

11.66 → 9.02

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Intellia Therapeutics Inc (NTLA) currently overvalued or undervalued?

What is Intellia Therapeutics Inc (NTLA) fair value?

NTLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Intellia Therapeutics Inc (NTLA) is between 5.25 to 50.18 according to relative valuation methord.

How does NTLA's valuation metrics compare to the industry average?

What is the current P/B ratio for Intellia Therapeutics Inc (NTLA) as of Dec 15 2025?

As of Dec 15 2025, Intellia Therapeutics Inc (NTLA) has a P/B ratio of 1.40. This indicates that the market values NTLA at 1.40 times its book value.

What is the current FCF Yield for Intellia Therapeutics Inc (NTLA) as of Dec 15 2025?

As of Dec 15 2025, Intellia Therapeutics Inc (NTLA) has a FCF Yield of -39.49%. This means that for every dollar of Intellia Therapeutics Inc’s market capitalization, the company generates -39.49 cents in free cash flow.

What is the current Forward P/E ratio for Intellia Therapeutics Inc (NTLA) as of Dec 15 2025?

As of Dec 15 2025, Intellia Therapeutics Inc (NTLA) has a Forward P/E ratio of -2.27. This means the market is willing to pay $-2.27 for every dollar of Intellia Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Intellia Therapeutics Inc (NTLA) as of Dec 15 2025?

As of Dec 15 2025, Intellia Therapeutics Inc (NTLA) has a Forward P/S ratio of 24.54. This means the market is valuing NTLA at $24.54 for every dollar of expected revenue over the next 12 months.

NTLA Valuation